文献速递肝病

Efruxifermin联合GLP-1受体激动剂治疗NASH/MASH合并2型糖尿病患者的随机2期研究的安全性与疗效

Safety and Efficacy of Efruxifermin in Combination With a GLP-1 Receptor Agonist in Patients With NASH/MASH and Type 2 Diabetes in a Randomized Phase 2 Study.
PubMed 文献 · Clin Gastroenterol Hepatol · 2024-03-04

本随机双盲安慰剂对照2b期研究纳入31例接受稳定GLP-1受体激动剂治疗的2型糖尿病合并MASH纤维化(F1-F3)成人,按2:1随机接受efruxifermin 50 mg每周一次或安慰剂治疗12周。Efruxifermin联合GLP-1受体激动剂耐受性良好,12周时肝脂肪分数降低65%,安慰剂组降低10%(P<.0001)。

要点

  • Efruxifermin 50 mg每周一次联合稳定剂量GLP-1受体激动剂治疗12周,耐受性良好。
  • 12周时efruxifermin组肝脂肪分数降低65%,安慰剂组降低10%(P<.0001)。
  • Efruxifermin改善了肝损伤和纤维化的无创标志物及糖脂代谢,同时维持GLP-1受体激动剂介导的体重下降。

核心结论

  • Efruxifermin联合GLP-1受体激动剂的耐受性特征与任一单药相当,同时显著降低MASH合并2型糖尿病患者的肝脂肪分数和无创纤维化标志物。
  • 作者认为,已使用GLP-1受体激动剂的患者加用efruxifermin可能进一步改善肝脏健康。

研究设计与样本

  • Cohort D为双盲、安慰剂对照的2b期研究,纳入接受稳定GLP-1受体激动剂治疗的2型糖尿病合并MASH纤维化(F1-F3)成人。
  • 受试者按2:1随机接受efruxifermin 50 mg(n=21)或安慰剂(n=10),每周一次,治疗12周。
  • 主要终点为在稳定剂量GLP-1受体激动剂基础上加用efruxifermin的安全性和耐受性。

主要发现

  • 31例受试者中,使用司美格鲁肽者占48.4%,度拉糖肽者占45.2%,利拉鲁肽者占6.5%。
  • 最常见的efruxifermin相关不良事件为轻至中度胃肠道事件。
  • 1例接受efruxifermin的患者因恶心停药,另1例撤回知情同意;无治疗相关严重不良事件。
  • 12周后,efruxifermin组肝脂肪分数降低65%,安慰剂组(单用GLP-1受体激动剂)降低10%(P<.0001 vs 安慰剂)。
  • Efruxifermin还改善了肝损伤、纤维化、糖代谢和脂代谢的无创标志物,同时维持了GLP-1受体激动剂介导的体重下降。

关键数值与推荐

  • Efruxifermin 50 mg每周一次,联合稳定剂量GLP-1受体激动剂,治疗12周。
  • 12周时肝脂肪分数较基线变化:efruxifermin组降低65% vs 安慰剂组降低10%(P<.0001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: In phase 2 studies, efruxifermin, an Fc-FGF21 analog, significantly reduced steatohepatitis and fibrosis in patients with non-alcoholic steatohepatitis, now called metabolic dysfunction-associated steatohepatitis (MASH), for which there is no approved treatment. Type 2 diabetes (T2D) and obesity are prevalent among patients with MASH and increasingly treated with glucagon-like peptide-1 receptor agonists (GLP-1RAs). This study evaluated the safety and efficacy of efruxifermin in patients with MASH, fibrosis, and T2D taking a GLP-1RA. METHODS: Cohort D was a double-blind, placebo-controlled, phase 2b study in adults with T2D and MASH with fibrosis (F1-F3) on stable GLP-1RA therapy randomized (2:1) to receive efruxifermin 50 mg or placebo, once weekly for 12 weeks. The primary endpoint was safety and tolerability of efruxifermin added to a stable dose of GLP-1RA. Secondary endpoints included changes in hepatic fat fraction (HFF), markers of liver injury and fibrosis, and metabolic parameters. RESULTS: Adults (N = 31) with T2D and MASH fibrosis (F1-F3) on a stable GLP-1RA (semaglutide, 48.4%; dulaglutide, 45.2%; liraglutide, 6.5%) received efruxifermin 50 mg (n = 21) or placebo (n = 10) for 12 weeks. The addition of efruxifermin to a GLP-1RA appeared safe and well-tolerated. The most frequent efruxifermin-related adverse events were mild to moderate gastrointestinal events. One patient receiving efruxifermin discontinued due to nausea, and another withdrew consent. There were no treatment-related serious adverse events. After 12 weeks, efruxifermin reduced HFF by 65% (P < .0001 vs placebo) compared with a 10% reduction for placebo (GLP-1RA alone). Efruxifermin also improved noninvasive markers of liver injury, fibrosis, glucose, and lipid metabolism while maintaining GLP-1RA-mediated weight loss. CONCLUSIONS: The tolerability profile of efruxifermin added to GLP-1RA appeared comparable to that of either drug alone, while also significantly reducing HFF and noninvasive markers of fibrosis in patients with MASH and T2D. Liver health in patients already on a GLP-1RA may be further improved by addition of efruxifermin. CLINICALTRIALS: gov, Number: NCT05039450.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Harrison SA, Frias JP, Lucas KJ, et al. Safety and Efficacy of Efruxifermin in Combination With a GLP-1 Receptor Agonist in Patients With NASH/MASH and Type 2 Diabetes in a Randomized Phase 2 Study. Clin Gastroenterol Hepatol. 2024. PMID: 38447814. doi:10.1016/j.cgh.2024.02.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。